Optimal Interstrand Bridge for Collagen Mimics
This application is a continuation of U.S. application Ser. No. 14/852,011, filed on Sep. 11, 2015, which claims the benefit of U.S. Provisional Application No. 62/049,550 filed on Sep. 12, 2014, each of which is incorporated by reference herein in its entirety. This invention was made with government support under AR044276 awarded by the National Institutes of Health. The government has certain rights in the invention. Collagen is the most abundant protein in vertebrates, occurring in virtually every tissue, including skin, tendon, bone, blood vessel, cartilage, ligament, and teeth. Collagen serves as the fundamental structural protein for vertebrate tissues. Collagen abnormalities are associated with a wide variety of human diseases, including arthritis, rheumatism, brittle bones, atherosclerosis, cirrhosis, and eye cataracts. Collagen is also critically important in wound healing. Collagen is a fibrous protein consisting of three polypeptide chains that fold into a triple helix (Jenkins & Raines, Collagen's biological significance has made collagen a common target for biomaterials engineering, encouraging the development of self-assembling synthetic peptide systems that mimic the triple-helical architecture of collagen. At the core of such synthetic peptide systems are collagen-mimetic peptides, or CMPs. Although many of these efforts employ non-covalent means to program strand association, the covalent cross-linking of strands remains the most robust strategy (see, e.g., Kinberger, G. A.; Cai, W. B.; Goodman, M. Collagen strands associate into triple helices with a single-residue stagger that gives rise to registers with an Xaa, Yaa, and Gly residue from each strand appearing at every cross-sectional plane along the triple helix, enabling cystine residues to be installed at proximal Xaa . . . Yaa pairs ( Consistent with this observation, natural cystine knots are known to interrupt the triple-helical structure of collagen (see Barth, D.; Kyrieleis, O.; Frank, S.; Renner, C.; Moroder, L. Accordingly, there is a need in the art for compositions and methods for optimizing covalent interstrand bridges in collagen-mimetic peptides and other synthetic collagen-like biomaterials by reducing the strain associated with conventional cystine (cysteine-cysteine or Cys-Cys) disulfide linkages. A cystine (Cys-Cys) disulfide bridge is a linkage that has been installed between collagen-mimetic peptide strands to help assemble collagen-like triple helices. However, Cys-Cys disulfide formation leads to a strained bridge which disrupts the resulting collagen-like triple helix. Here, we disclose an improved disulfide linkage between collagen-mimetic peptide strands, a disulfide covalent bond between a homocysteine (one carbon longer than cysteine) in the canonical Xaa position of a first collagen-mimetic peptide strand and a cysteine in the canonical Yaa position of a second collagen-mimetic peptide strand. In the structure shown below, R1, R2, R3, and R4, represent the rest of the peptide chain. In silico screening of all possible linkages identified the disulfide bridge between proximal homocysteine (Hcy) and cysteine (Cys) as conferring much greater stability than a Cys-Cys bridge, but only when Hcy is installed in the Xaa position of the canonical Xaa-Yaa-Gly repeat and Cys is installed in the Yaa position. Thus, a Hcy-Cys bridge is markedly superior to a Cys-Hcy bridge. We synthesized all of the 1,2 combinations and found that collagen mimetic peptides (CMPs) validate this design. Only Hcy-Cys bridges improved triple-helical structure and stability upon disulfide-bond formation. Thus, this specific linker design will enhance CMP-based biomaterials and enable previously inaccessible molecular designs. Accordingly, in a first aspect, the disclosure encompasses a collagen-mimetic peptide comprising the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:17), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is zero or any positive integer, and m is zero or any positive integer. The core amino acid sequence encompassed by this general formula, (Xaa-Yaa-Gly)-Hcy-Yaa-Gly-(Xaa-Yaa-Gly), is SEQ ID NO:1. In some embodiments, each Xaa and each Yaa is independently selected from the group consisting of proline, hydroxyproline, and an amino acid residue having a side chain capable of being functionalized. Amino acid residues having a side chain capable of being functionalized may include, as non-limiting examples, an amine, an alkene, an aldehyde, an alkyne, an azide, or a thiol. One specific non-limiting example of such an amino acid residue is lysine. In some embodiments, each Xaa is proline and each Yaa is hydroxyproline or proline. In some embodiments, at least one Xaa or Yaa is an amino acid residue having a side chain capable of being functionalized, and this amino acid residue is attached to a cargo moiety, such as a therapeutic agent or a detection agent. In some embodiments, n is an integer from 0 to 16, m is an integer from 0 to 16, and the sum of n+m is from 0 to 16. In some embodiments, the collagen-mimetic peptide consists essentially of the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:18), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is an integer from 0 to 16, m is an integer from 0 to 16, and the sum of n+m is from 0 to 16. In a second aspect, the disclosure encompasses a multi-stranded collagen-mimetic peptide comprising (a) a first strand comprising the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:17), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is zero or any positive integer, and m is zero or any positive integer; and (b) a second strand comprising the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q(SEQ ID NO:19), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, p is zero or any positive integer, and q is zero or any positive integer. The core amino acid sequence encompassed by this general formula, (Xaa-Yaa-Gly)-Xaa-Cys-Gly-(Xaa-Yaa-Gly), is SEQ ID NO:2. The first and second strands are covalently bonded with a disulfide bond between the sulfur atom of the thiol side chain of the homocysteine residue of the first strand and the sulfur atom of the thiol side chain of the cysteine residue of the second strand. In some embodiments, each Xaa and each Yaa is independently selected from the group consisting of proline, hydroxyproline, and an amino acid residue having a side chain capable of being functionalized. In some non-limiting embodiments, the amino acid residue having a side chain capable of being functionalized is lysine. In some embodiments, each Xaa is proline and each Yaa is hydroxyproline or proline. In some embodiments, at least one Xaa or Yaa is an amino acid residue having a side chain capable of being functionalized, and this amino acid residue is attached to a cargo moiety, such as a therapeutic agent or a detection agent. In some embodiments, n is an integer from 0 to 16, m is an integer from 0 to 16, the sum of n+m is from 0 to 16, p is an integer from 0 to 16, q is an integer from 0 to 16, and the sum of p+q is from 0 to 16. In some embodiments, the first strand consists essentially of the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:18), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is an integer from 0 to 16, m is an integer from 0 to 16, and the sum of n+m is from 0 to 16; and the second strand consists essentially of the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q(SEQ ID NO:20), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, p is an integer from 0 to 16, q is an integer from 0 to 16, and the sum of p+q is from 0 to 16. In some embodiments, the multi-stranded collagen-mimetic peptide consists essentially of the first strand and the second strand joined with a covalent disulfide bond, as described above. In some embodiments, the second strand comprises the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q-Hey-Yaa-Gly-(Xaa-Yaa-Gly)r(SEQ ID NO:21) (the core sequence (Xaa-Yaa-Gly)-Xaa-Cys-Gly-(Xaa-Yaa-Gly)-Hey-Yaa-Gly-(Xaa-Yaa-Gly) is SEQ ID NO:3) or (Xaa-Yaa-Gly)p-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)q-Xaa-Cys-Gly-(Xaa-Yaa-Gly)r(SEQ ID NO:22) (the core sequence (Xaa-Yaa-Gly)-Hey-Yaa-Gly-(Xaa-Yaa-Gly)-Xaa-Cys-Gly-(Xaa-Yaa-Gly) is SEQ ID NO:4), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and p, q and r are independently zero or any positive integer. In some such embodiments, the multi-stranded collagen-mimetic peptide further includes a third strand comprising the formula (Xaa-Yaa-Gly)j-Xaa-Cys-Gly-(Xaa-Yaa-Gly)k(SEQ ID NO:23), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and j and k are independently zero or any positive integer. The second and third strands are covalently bonded with a disulfide bond between the sulfur atom of the thiol side chain of the homocysteine residue of the second strand and the sulfur atom of the thiol side chain of the cysteine residue of the third strand. In some such embodiments, (n+m+1)=(p+q+r+2), (p+q+r+2)=(j+k+1), or both. In yet other such embodiments, one of the homocysteine residues is substituted with a cysteine residue, such that either the first and second or the second and third strands are covalently bonded with a Cys-Cys disulfide bond. In a third aspect, the disclosure encompasses a synthetic collagen-like fibrillar assembly that includes a plurality of the multi-stranded collagen-mimetic peptides, as described above. Some such embodiments encompass a composition that includes the synthetic collagen-like fibrillar assembly and a therapeutic agent, such as a growth factor. In a fourth aspect, the disclosure encompasses a kit that includes a plurality of the multi-stranded collagen-mimetic peptides described above. In some embodiments, the kit may further include a therapeutic agent, such as a growth factor. In a fifth aspect, the disclosure encompasses a method of making a collagen-mimetic peptide. The method includes the step of substituting a non-homocysteine Xaa residue in a peptide comprising the formula (Xaa-Yaa-Gly)n, wherein Gly is glycine, each Xaa and each Yaa is independently any amino acid residue, and n is zero or any positive integer, with a homocysteine residue. In some embodiments, the non-homocysteine Xaa residue that is substituted with homocysteine is a proline residue. In some embodiments, each unsubstituted Xaa and each Yaa is independently selected from the group consisting of proline, hydroxyproline, and an amino acid residue having a side chain capable of being functionalized. In some embodiments, each unsubstituted Xaa is proline and each Yaa is proline or hydroxyproline. In a sixth aspect, the disclosure encompasses a method of making a multi-stranded collagen-mimetic peptide. The method includes the step of forming a covalent disulfide bond between a first strand comprising the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:17), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is zero or any positive integer, and m is zero or any positive integer; and a second strand comprising the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q(SEQ ID NO:19), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, p is zero or any positive integer, and q is zero or any positive integer. The covalent disulfide bond is formed between the sulfur atom of the thiol side chain of the homocysteine residue of the first strand and the sulfur atom of the thiol side chain of the cysteine residue of the second strand. In some embodiments, each Xaa and each Yaa is independently selected from the group consisting of proline, hydroxyproline, and an amino acid residue that is capable of being functionalized. In some embodiments, each Xaa is proline and each Yaa is proline or hydroxyproline. In some embodiments, the first strand consists essentially of the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m(SEQ ID NO:18), wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, n is an integer from 0 to 16, m is an integer from 0 to 16, and the sum of n+m is from 0 to 16; and the second strand consists essentially of the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q(SEQ ID NO:20), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, p is an integer from 0 to 16, q is an integer from 0 to 16, and the sum of p+q is from 0 to 16. In some embodiments, the method further includes the step of forming a covalent disulfide bond between the sulfur atom of the thiol side chain of the homocysteine residue of the second strand and the sulfur atom of the thiol side chain of the cysteine residue of a third strand, wherein the third strand comprises the formula (Xaa-Yaa-Gly)j-Xaa-Cys-Gly-(Xaa-Yaa-Gly)k(SEQ ID NO:23), wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and j and k are independently zero or any positive integer. In a seventh aspect, the disclosure encompasses a method of making a synthetic collagen-like fibrillar assembly. The method includes the step of contacting a first multi-stranded collagen-mimetic peptide as described above with one or more second multi-stranded collagen-mimetic peptides as described above. The first and second multi-stranded collagen-mimetic peptides self-assemble into a larger synthetic collagen-like fibrillar assembly. In an eighth aspect, the disclosure encompasses a method of facilitating wound healing. The method includes the step of contacting a wound with a composition that includes the multi-stranded collagen-mimetic peptide described above, or the synthetic collagen-like fibrillar assembly described above, thereby facilitating the healing of the wound. In some embodiments, the composition further includes a therapeutic agent, such as a growth factor. In a ninth aspect, the disclosure encompasses the use of the collagen-mimetic peptide described above or the synthetic collagen-like fibrillar assembly described above to facilitate wound healing in a subject. In a tenth aspect, the disclosure encompasses the use of the collagen-mimetic peptide described above, the multi-stranded collagen-mimetic peptide described above, or the synthetic collagen-like fibrillar assembly described above in the manufacture of a medicament to facilitate wound healing in a subject. Other objects, advantages, and features of the present invention will become apparent upon review of the specification, drawings, and claims. We disclose herein an improved linkage between collagen-mimetic peptide strands: a disulfide covalent bond between a homocysteine in the canonical Xaa position of a first collagen-mimetic peptide strand and a cysteine in the canonical Yaa position of a second collagen-mimetic peptide strand. In native collagen, the polyproline type II helices consist of over 300 repeats of the unit Xaa-Yaa-Gly. Although in native collagen, Xaa is often (2S)-proline (Pro) and the Yaa is often (2S,4R)-4-hydroxyproline (Hyp), any amino acid residue may occur at these positions. Accordingly, the Xaa and Yaa position residues of the disclosed collagen-mimetic peptides can be any amino acid. In some non-limiting embodiments, Xaa and Yaa are selected from proline, hydroxyproline, or lysine. For ease of synthesis, proline is sometimes used in both the Xaa and Yaa positions in collagen-mimetic peptide strands. The use of hydroxyproline in the Yaa position may improve the stability of the collagen-like triple helix. However, any other amino acid or amino acid derivatives may be used at the Xaa and Yaa positions, including without limitation those disclosed in U.S. Patent Publication No. 2007/0275897, which is incorporated by reference herein. To improve functionality, the collagen-mimetic peptides may be functionalized with any desired moiety. As a non-limiting example, lysine may be included in the sequence of the collagen-mimetic peptides (CMPs) so that fluorophores, therapeutics or other cargo can be attached to the growing assembly at the Nε C atom. However, Lys is not the only residue that could facilitate such attachment, and other side-chains could be used, as well. For example, side chains containing alkenes, alkynes, aldehydes, azides, and thiols could be all be used for this purpose. Accordingly, any amino acid residue capable of being functionalized may be included at the Xaa or Yaa position to facilitate functionalizing the collagen-mimetic peptide. The amino side chain of lysine or any other amino acid residue capable of being functionalized may be functionalized with a desired moiety using standard synthetic techniques known in the art. The addition of the desired moiety on the amino side chain terminus can be done separately from the formation of the disulfide bridge formation, so that the assembly of the multi-stranded collagen-mimetic peptide is not affected. Alternatively, the disulfide bridge itself may be subsequently broken and functionalized at the terminal thiol, as desired, using methods known in the art. The disclosed collagen-mimetic peptides, multi-stranded collagen-mimetic peptides, and synthetic collagen-like fibrillar assemblies have a variety of potential applications, including without limitation in biomaterials used for tissue repair and/or tissue engineering. As a non-limiting example, the disclosed collagen-mimetic peptides may be used to treat wounded tissue or to facilitate the delivery of therapeutic agents or cytoactive factors to acute or chronic tissue wounds. Compositions containing collagen-mimetic peptides may be used for wound dressing, in dural closures, for reinforcement of compromised tissues, and in guided tissue regeneration. Such compositions can be used as vehicles for the sustained release of pharmaceuticals or therapeutic agents, including without limitation antibiotics or growth factors, such as recombinant human growth factor (hGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), or neuropeptides, such as Substance P. Therapeutics, such as growth factors, can be attached to self-assembling linked-dimers to aid in wound healing. However, therapeutic delivery could also be realized with a similar system that does not self-assemble. Blunt-ended linked dimers, such as those disclosed in Examples 1 and 2 below, can be loaded with cargo, and administered to the wound site, in a manner similar to what is currently done with single strands. Thus, using a “plurality” of linked-dimers would not be necessary. As another non-limiting example, the disclosed collagen-mimetic peptides may be used in cell culture scaffold compositions for both in vivo and in vitro applications. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although suitable methods and materials for the practice or testing of the present invention are described below, other methods and materials similar or equivalent to those described herein, which are well known in the art, can also be used. The following Examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and the following examples and fall within the scope of the appended claims. In some natural collagen triple helices, cysteine (Cys) residues on neighboring strands are linked by disulfide bonds, enhancing association and maintaining proper register. Similarly, Cys-Cys disulfide bridges have been used to impose specific associations between collagen-mimetic peptides (CMPs). In this example, screening a library of disulfide linkers in silico for compatibility with collagen identified the disulfide bridge between proximal homocysteine (Hcy) and Cys as conferring much greater stability than a Cys-Cys bridge, but only when Hcy was installed in the Xaa position of the canonical Xaa-Yaa-Gly repeat and Cys was installed in the Yaa position. Experimental evaluation of CMPs that host alternative thiols validated this design: only Hcy-Cys bridges improved triple-helical stability upon disulfide-bond formation. This privileged linker can enhance CMP-based biomaterials and enable previously inaccessible molecular designs. Introduction. Cystine “knots”—complex arrangements of interstrand Cys-Cys disulfide bridges—are found in natural fibrillar and fibril-associated collagens, inspiring the use of Cys-Cys bridges in synthetic collagen-like fibrillar assemblies that extend through sticky ends. In this Example, we determined the effect of this natural disulfide bridge and synthetic alternatives on triple-helix stability. The amino-acid sequence of natural collagen is defined by repeating (Xaa-Yaa-Gly) units that feature (2S)-proline (Pro) and (2S,4R)-4-hydroxyproline (Hyp) at the Xaa and Yaa positions, which favor the formation of polyproline-type II helices. Collagen strands associate into triple helices with a single-residue stagger that gives rise to registers with an Xaa, Yaa, and Gly residue from each strand appearing at every cross-sectional plane along the triple helix, enabling cystines to be installed at proximal Xaa . . . Yaa pairs ( An examination of neighboring Xaa . . . Yaa pairs in a [(PPG)10]3crystal structure (PDB entry 1kf6)9((PPG)10is SEQ ID NO:6) reveals the Xaa . . . Yaa Cβ . . . Cβ distance (5 Å) to be longer than the average Cβ . . . Cβ distance (4 Å) predicted for a cystine. Thus, even neighboring Xaa and Yaa positions might not allow a geometry favorable for disulfide-bond formation. Natural cystine knots interrupt triple-helical structure, but any effect on collagen function is compensated by the length of common collagen strands, which have about 103residues. In contrast, CMPs in typical synthetic assemblies are only ˜30 residues long, and could be more susceptible to an adverse impact from the strain of a cystine linkage. General Experimental Design, Results, and Discussion. We reasoned that relieving strain within the disulfide bridge could be the key step toward an interstrand “staple” that conforms to the collagen triple helix. Toward this end, we used molecular modeling to explore longer linkers that employ combinations of cysteine (Cys) and the homologated analogs homocysteine (Hcy) and thionorvaline (Tnv), which have one, two, and three side-chain methylene groups, respectively ( Increasing linker length relieves the strain on the disulfide. The value of Estrainis largest for the c-c bridge, which contains only two methylene groups ( Interestingly, the h-c disulfide (Xaa=Hcy; Yaa=Cys) falls outside this trend and is free of strained torsions. Despite being among the shortest linkers in the set, h-c forms the most stable disulfide bridge: 12 kcal/mol lower in energy than c-c. The Xaa and Yaa positions are not related by symmetry, and the c-h bridge does not show the dramatic reduction in the value of Estrainas does the h-c bridge. To validate our computational predictions, we synthesized CMPs poised to form a c-c, h-c, c-h, or h-h bridge. This set includes bridges predicted to be the best (h-c) and worst (c-c). The disulfide-linked [(PPG)10]3variants were constructed and characterized using methods established previously ( The disulfide-linked variants share with [(PPG)10]3the characteristic CD signature of a collagen triple helix ( A marked loss in the thermostability of triple helices was observed for all disulfide-linked variants, except that with an h-c bridge ( The large destabilizing effect of replacing a proline residue with Cys or Hcy ( To verify this prediction, we assessed equimolar mixtures of s1x, s2, and s3y in thermal denaturation experiments. The resulting Tmvalues near 31° C. for “reduced” x·y·s2 complexes agree closely with the predicted values ( Our calculations correctly predict the h-c bridge to be the least strained and thus most stabilizing linker. Still, for strained linkers the Tmvalues do not correlate with computational rankings (cf. We propose the Hcy-Cys interstrand disulfide bridge as a superior alternative to Cys-Cys for collagen-like peptides and proteins. We expect facile integration of this staple into Xaa-Yaa-Gly repeats, as Hcy-Cys bridges conform well to the collagen fold. Self-assembling systems that grow through the sticky-ended assembly of triple-helical units rely on two interstrand bridges and will benefit from our discovery (see, e.g., Koide, T.; Homma, D. L.; Asada, S.; Kitagawa, K. Computational Methodology and Results. Computational Design and Evaluation of Disulfide Bridges Between (PPG)10Strands. All calculations were performed on Intel Xeon 2.33-GHz processors at the Materials and Process Simulation Center in California Institute of Technology (Pasadena, Calif.). Computational models were built on the crystal structure of the (PPG)10trimer (PDB entry 1kf6) (Berisio, R.; Vitagliano, L.; Mazzarella, L.; Zagari, A. Proline residues in the Xaa and Yaa positions selected for linkage were replaced with Cys, Hcy, or Tnv. The new side-chains were minimized on trimers that contain both Cys-analogs on neighboring positions, and the pre-disulfide formation energies, Ex·ywere determined. The thiol hydrogens were omitted from these models to maintain the same number of atoms before and after disulfide formation. The configurations of the disulfide-bonded linkers were optimized, first by minimization and then by multiple rounds of simulated annealing. Post-disulfide formation energies, Ex−ywere determined on the resulting models. The energy change due to disulfide formation was calculated as Estrain=Ex−y−Ex·y. The intent of this metric is to quantify changes in bonding and steric interactions, and allow their comparison across linkers. The omission of solvation and Coulombic contributions from the model help reduce noise and focus results on local interactions. Linker Strain in Relation to Torsion Angles. The h-c linker is predicted to be least strained by the computational analysis, as shown in Table Si. Strained bond lengths and bond angles are responsible for the poor performance of c-c and c-h linkers, whereas high torsion energies and, for t-t and t-c, van der Waals energies are observed for linkers other than h-c. Overall, linkers that have a longer side chain at the Xaa position than Yaa (nXaa>nYaa) perform better than those with shorter (nXaa<nYaa) or analogous side chains (nXaa=nYaa). The torsion angles across each C—C, C—S, or S—S bond on the linker models are presented in Table 2. The C—C and C—S torsion angles on the linkers can be categorized into two groups: near-eclipsed (|χ|=0°-30° or 90°-150°) or near-staggered (|χ|=30°-90° or 150°-180°. The high torsion energies correlate with the occurrence of near-eclipsed torsion angles across C—C bonds, most often between Cβ and Cγ. The h-c linker is the only one that does not harbor strained torsion angles according to this simple criterion. Experimental Methodology and Results. Peptide Synthesis. All (PPG)10(SEQ ID NO:6) and (PPG)10-variants were synthesized on Wang or polyethylene glycol-based resins using a Prelude (Protein Technologies) peptide synthesizer at room temperature using standard Fmoc chemistry at the University of Wisconsin—Madison Biotechnology Center. Condensation of Fmoc-ProProGly-OH tripeptide segments was employed with all peptides wherever applicable, except for the C-terminal PPG section where proline residues were added individually on glycine-preloaded resins. Synthesis of Fmoc-ProProGly-OH was described previously (Jenkins, C. L.; Vasbinder, M. M.; Miller, S. J.; Raines, R. T. Peptides were cleaved from the resin and deprotected in reagent R (90:5:3:2 TFA:thioanisole:ethanedithiol:anisole; 1.5-2.0 mL), precipitated from methyl t-butyl ether below 0° C., and isolated by centrifugation. Dried crude peptides were dissolved in 0.1% v/v TFA and filtered and purified by preparative HPLC at 45° C. using gradients of CH3CN/water containing 0.1% v/v TFA on a Shimadzu Prominence unit equipped with a Macherey—Nagel VarioPrep 250/21 C18 column. All peptides were >90% pure according to analytical HPLC and MALDI—TOF mass spectrometry (MS). MALDI—TOF analysis was carried out on an Applied Biosystems Voyager DE-Pro mass spectrometer at University of Wisconsin—Madison Biophysics Instrumentation Facility (BIF). Both single peptides and linked-dimers were analyzed using a 10:1 matrix mixture of 2-(4-hydroxyphenylazo)benzoic acid: α-cyano-4-hydroxycinnamic acid to suppress the reduction of disulfide bonds due to in-source decay (see Huwiler, K. G.; Mosher, D. F.; Vestling, M. M. Synthesis of Linked-Dimers. Disulfide-linked strand dimers were produced by coupling 2,2′-dithiobis(5-nitropyridine)-(DTNP)-activated thiols on an s3y strand with free thiols on an s1x strand ( Coupling of s1x and s3y-Npys was initiated by mixing equimolar amounts of the components (2.2 mM final concentration) dissolved previously in degassed and argon-saturated 50 mM NH4OAc buffer, pH 5.3. Reactions were stirred under argon for ≥6 h, after which the solution was acidified and the solvent was removed by lyophilization. Disulfide-linked s1x−s3y dimers were isolated by HPLC and analyzed by MALDI—TOF mass spectrometry as described above. For x−y linked-dimers, (m/z) [M+H]+ calcd 5072.8, found 5073.2 for c-c; calcd 5086.8, found 5086.1 for c-h; calcd 5100.8, found 5100.6 for h-h; calcd 5086.8, found 5086.3 for h-c; calcd 2530.3, found 2530.0 for s2. Analytical HPLC results for purified linked-dimers in 50 mM HOAc are presented in Sample Preparation. Samples were prepared and experiments were conducted as reported previously (Kotch, F. W.; Raines, R. T. Circular Dichroism (CD) Spectroscopy. CD spectra for all samples were acquired at 4° C. with a 1-nm band-pass in quartz cuvettes with a 0.1-cm pathlength, using an averaging time of 3 s. For thermal denaturation experiments the CD signal was monitored at 226 nm while the sample was heated from 4 to 64° C. in 3-° C. steps over 4.5 h. All samples were prepared at a strand concentration of 180 μM except for s1x+s2+s3y mixtures, which were prepared at a total peptide concentration of 270 μM in anticipation of complex melting transitions. Due to weak signal, the s1h peptide was tested at 360 μM as well as 180 μM to allow for a more accurate determination of the Tmvalue. CD data from denaturation experiments were converted to fraction folded, and data near 50% folded were used to obtain the Tmvalues for each sample, which are reported in Table 3. CD data were acquired on CD spectrometers from Aviv Biomedical (Lakewood, N.J.). These spectrometers were an Aviv 202SF and 420 in the BIF, and an Aviv 420 in the Gellman Laboratory of the Department of Chemistry, all of them equipped with a 5-cell thermoelectric sample changer. Data on 180 μM s2 were collected in every experiment to allow comparison of instrument performance and to account for differences in wavelength calibration. Our results were well reproducible between instruments (Tm=36.5±0.6° C. for 180 μM s2; n=5). All CD spectra and melting curves are discussed in this study are shown in Analytical Ultracentrifugation (AUC). Sedimentation equilibrium experiments were performed at the BIF with a Beckman XL-A analytical ultracentrifuge equipped with an An-60 Ti rotor. Samples were prepared at a strand concentration of 180 μM, but were diluted to a concentration of 90 μM before the experiment. Sample (100 μL) and buffer (110 μL) were placed in a cell with a 12-mm double-sector charcoal-filled centerpiece (Epon). Experiments were run at 4° C. at speeds of 12, 22, 32, and 42 k rpm, and gradients recorded at 231 nm were monitored until they were superimposable when recorded 4 h apart. A buffer density of 1.00037 g/mL and a partial specific volume of 0.7275 mL/g calculated based on amino acid content for (PPG)10was used. Equilibrium gradients at 4° C. were modeled as single and multiple non-interacting species through nonlinear least-squares fits to gradient data. Analysis was performed with programs written for IGOR PRO (WaveMetrics, Lake Oswego, Oreg.) by D. R. McCaslin (University of Wisconsin). Non-sedimenting baselines between 0.03-0.05 OD were applied for all samples, whereas 0.07 OD was used for the x−y·s2 construct featuring a c-c linker. Plots of gradients and fits are shown in Overall, the data collected on x−y·s2 variants fitted best to a triple-helical model (single species with MW=7.6 kDa). A similar model does not explain the s2 data. In addition to triple helices, consideration of free (PPG)10strands in the model was necessary for satisfactory description of s2 gradients. Among x−y·s2 variants, the samples that feature h-c, c-h and h-h linkers behave as triple-helical units. Even though the c-c case forms gradients similar to others, models that consider triple-helices work best either with large baseline corrections, or when strand-dimers are considered in the model in addition to triple helices. It is likely that the actual composition for this sample includes triple helices, together with low levels of strand-monomers and dimers. Such issues are not observed with linkers predicted to be less strained. In this example, we extended the evaluation of the disulfide bridges reported in Example 1 to analogous thioether bridges having the sulfur atom in the thiol side chain of a cysteine (Cys), homocysteine (Hcy), or thionorvaline (Tnv) residue in one CMP strand covalently bonded to the terminal carbon atom in the alkyl side chain of a homoalanine (Hal), norvaline (Nva), or norleucine (Nle) residue in an adjacent CMP strand. Such bonds can be built and assessed in silico. However, as the skilled artisan would understand, thioether linkages are chemically synthesized by directly forming such covalent bonds. The disulfide bridges having the sulfur atom in the thiol side chain of a cysteine (Cys), homocysteine (Hcy), or thionorvaline (Tnv) residue in one CMP strand covalently bonded to the sulfur atom in the thiol side chain of a cysteine (Cys), homocysteine (Hcy), or thionorvaline (Tnv) residue in an adjacent CMP strand, as previously described in Example 1, were also included in this comparison. The structures of the listed amino acid residues and a schematic of the evaluated combinations is shown in Accordingly, this Example summarizes the data for 23 different covalent bridges between an Xaa residue of a first CMP strand and a Yaa residue of a second CMP strand. These 23 bridges include the nine disulfide bridge combinations disclosed in Example 1 (Xaa-Yaa is Cys-Cys, Cys-Hcy, Cys-Tnv, Hcy-Cys, Hcy-Hcy, Hcy-Tnv, Tnv-Cys, Tnv-Hcy, or Tnv-Tnv), and 14 additionally disclosed thioether bridge combinations (Xaa-Yaa is Cys-Hal, Cys-Nva, Cys-Nle, Hcy-Hal (or the equivalent, Hal-Hcy), Hcy-Nva (or the equivalent, Hal-Tnv), Hcy-Nle, Tnv-Hal (or the equivalent, Nva-Hcy), Tnv-Nva (or the equivalent, Nva-Tnv), Tnv-Nle, Hal-Cys, Nva-Cys, Nle-Cys, Nle-Hcy, or Nle-Tnv). Estrainfor each of each of these 23 Xaa-Yaa bridges was calculated using the methods described in Example 1. Table 4 presents the results grouped by bridge length (i.e., from 3 to 7 bonds between linker β-carbon atoms), then ordered within each group from low to high total Estrain. Table 5 presents the same results ordered from low to high total Estrain, without regard to bridge length. The sum of bond and angle strain components to Estrainare reported together under “Bonds” in both tables. As in Example 1, the disulfide Xaa-Yaa bridge comprising Hcy-Cys had substantially lower Estrainthan any other bridge. The results are shown graphically in In previous work, Koide et al. (Bioorg. Med. Chem. Lett. (2005) 15:5230-5233) used two interstrand Cys-Cys disulfide bridges to connect three CMP strands (see In this example, we outline the application of the optimal interstrand disulfide bridge described above to the construction of a three-stranded polypeptide having two separate disulfide bridges between the strands, similar to the generic structure shown in The disclosed Hcy-Cys bridge may be used to produce three chemically-linked strands that could subsequently be used for self-assembly, as described further in Example 4 (see, e.g., In some such embodiments, one of the Hcy-Cys linkages may be replaced with Cys-Cys, and utilize the Hcy-Cys bridge in that way. In one non-limiting example, a three-stranded polypeptide would have the following structure(Cys-Cys and Hcy-Cys bridges bold and underlined): In other embodiments, the middle strand may have a sequence that puts the Cys and Hcy in reverse order: (Xaa-Yaa-Gly)p-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)q-Xaa-Cys-Gly-(Xaa-Yaa-Gly)r(SEQ ID NO:22). In one non-limiting example, a three-stranded polypeptide would have the following structure (Hcy-Cys bridge bold and underlined between strands): In this example, we outline the application of the two-stranded CMP units made with the optimal interstrand disulfide bridge described above (a covalent disulfide bond between an Xaa Hcy residue on one CMP strand and a Yaa Cys residue on another CMP strand) to the construction of larger collagen-like fibrillar assemblies made of a plurality of polypeptides containing the optimal interstrand disulfide bridge. As noted above, it has been previously shown that three-stranded units made using two interstrand Cys-Cys disulfide bridges to connect three CMP strands can self-assemble into larger fibrillar structures. However, such constructs are difficult to synthesize, because the presence of multiple disulfide bridges necessitates successive differential deprotection and coupling steps. Synthesis of two-stranded assembling units would be simpler and avoid such complications. However, two-stranded units cannot form triple-helical structure prior to assembly. Therefore, a linker with high Estrain(e.g. Cys-Cys) would cause bigger distortions to the peptide structure and make it less collagen-like when applied to a free two-stranded assembling unit rather than a free three-stranded unit with an already-formed triple-helical core. Thus, assembly kinetics and stability of two-stranded units will be more sensitive to a linker with high Estrain. Because the optimal Hcy-Cys Xaa-Yaa disulfide interstrand bridge of the present invention results in a substantially reduced Estrain, it is now possible to synthesize collagen-like fibrillar assemblies using covalently-bonded two-stranded units that do not exhibit bridge-induced disruptions to their collagen-like structure. The two-stranded units are synthesized with ease through a single coupling step forming the Hcy-Cys Xaa-Yaa disulfide interstrand bridge between the CMP strands, rather than the multiple deprotection and coupling steps required for three-stranded units. Such constructs may also feature overhanging “sticky ends” ( Each strand can be strictly designed for strand and overhang size and composition, resulting in a customized “puzzle piece” that is designed to self-assemble into a desired fibrillar assembly. A wide variety of fibrillar assemblies can be engineered using the customized “puzzle” units that include the Hcy-Cys Xaa-Yaa disulfide interstrand bridge of the present invention ( As noted above, self-assembling systems have been designed using Cys-Cys disulfide bridges as linkers in the past. In these systems, self-assembly proceeds through the association of “sticky-ends,” which predominantly relies on the recognition of a single-stranded “overhang” by a double-stranded “overhang.” Because Hcy-Cys bridges do not distort the collagen backbone as much as Cys-Cys bridges, this recognition is more robust when Hcy-Cys is used instead of Cys-Cys. Furthermore, because Hcy-Cys is less destabilizing than Cys-Cys, the assembling units can be made smaller in size, both in regards to the length of peptides, and in regards to the number of strands. In addition, because Hcy-Cys bridges cause minimal disruptions to the local structure, they can be more easily applied to any site along the peptide chain. In a non-limiting example, we have prepared a two-stranded self-assembling unit by connecting two (POG)8(SEQ ID NO:15) strands with a Hcy-Cys disulfide bridge to produce an offset that could support sticky-ended self-assembly. “O” represents hydroxyproline. This offset allows multiple 2-stranded units to associate into a triple helix that supports sticky ends for further extension ( The assemblies exhibit the characteristic collagen signature peak at ˜225 nm on circular dichroism spectra and produce broad melting profiles similar to those observed on a three-stranded system (Kotch, F. W.; Raines, R. T. In sum, our results suggest that assembly through two-stranded CMP constructs is indeed possible and that the Hcy-Cys disulfide linker is compatible with this process. Further details necessary for tuning assembly properties of this system for bio- and nano-technology applications can be determined through further experimentation. The invention is not limited to the embodiments set forth herein for illustration, but includes everything that is within the scope of the claims. Furthermore, all references cited herein are hereby incorporated by reference in their entirety and for all purposes as if fully set forth herein. This specification includes the sequence listing that is concurrently filed in computer readable form. This sequence listing is incorporated by reference herein. Novel collagen-mimetic peptides are disclosed comprising the formula (Xaa-Yaa-Gly)n, where the amino acid at one of the Xaa positions is substituted with a homocysteine residue. Also disclosed are multi-stranded novel collagen-mimetic peptides comprising a first strand as described above that is covalently bonded with a disulfide bridge to a second strand comprising the formula (Xaa-Yaa-Gly)m, where the amino acid at one of the Yaa positions is substituted with a cysteine residue. Disulfide formation between the terminal thiol sulfur of the homocysteine residue of the first strand and the terminal thiol sulfur of the cysteine residue of the second strand reveals unstrained bridges that enhance the structure and substantially improve the stability of collagen triple helices as compared to other possible disulfide or thioether bridges. Thus, the disclosed collagen mimetic peptides have improved stability, and can be used to produce optimized collagen-like fibrillar assemblies for wound healing and other biomedical applications. 1. (canceled) 33. A multistrand collagen-mimetic peptide comprising
(a) a first strand consisting of the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)mor (Xaa-Yaa-Gly)n-Cys-Yaa-Gly-(Xaa-Yaa-Gly)m, wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, and (i) n is an integer from 0-16 and m is an integer from 1-16, or (ii) n is an integer from 1-16 and m is an integer from 0-16; (b) a second strand consisting of the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)ror (Xaa-Yaa-Gly)p-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)q-Xaa-Cys-Gly-(Xaa-Yaa-Gly)r, wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and (i) p, q and r are independently selected from an integer from 0-16; wherein n+m+1=p+q+r+2; and wherein the first and second strands are covalently bonded with a disulfide bond between the sulfur atom of the thiol side chain of the homocysteine residue of the first strand and the sulfur atom of the thiol side chain of the cysteine residue of the second strand. 34. The multi-stranded collagen-mimetic peptide of 35. The multi-stranded collagen-mimetic peptide of 36. The multi-stranded collagen-mimetic peptide of 37. The multi-stranded collagen-mimetic peptide of wherein the second and third strands are covalently bonded with a disulfide bond between the sulfur atom of the thiol side chain of the homocysteine residue of the second strand and the sulfur atom of the thiol side chain of the cysteine residue of the third strand. 38. The multi-stranded collagen-mimetic peptide of 39. The multi-stranded collagen-mimetic peptide of 40. The multi-stranded collagen-mimetic peptide of 41. A synthetic collagen-like fibrillar assembly comprising a plurality of the multi-stranded collagen-mimetic peptides of 42. A composition comprising the synthetic collagen-like fibrillar assembly of 43. A kit comprising a plurality of the multi-stranded collagen-mimetic peptides of 44. The kit of claim 13, further comprising a therapeutic agent. 45. A method of making a multi-stranded collagen-mimetic peptide comprising forming a covalent disulfide bond between a first strand consisting of the formula (a) a first strand consisting of the formula (Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)mor (Xaa-Yaa-Gly)n-Cys-Yaa-Gly-(Xaa-Yaa-Gly)m, wherein Gly is glycine, Hcy is homocysteine, each Xaa and each Yaa is independently any amino acid residue, and (i) n is an integer from 0-16 and m is an integer from 1-16, or (ii) n is an integer from 1-16 and m is an integer from 0-16;
(b) a second strand consisting of the formula (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)ror (Xaa-Yaa-Gly)p-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)q-Xaa-Cys-Gly-(Xaa-Yaa-Gly)r, wherein Gly is glycine, Cys is cysteine, each Xaa and each Yaa is independently any amino acid residue, and p, q and r are independently selected from a integer from 0-16; wherein (n+m+1)=(p+q+r+2); and wherein the covalent disulfide bond is formed between the sulfur atom of the thiol side chain of the homocysteine residue of the first strand and the sulfur atom of the thiol side chain of the cysteine residue of the second strand. 46. The method of 47. The method of 48. The method of 49. A method of making a synthetic collagen-like fibrillar assembly, comprising contacting a first multi-stranded collagen-mimetic peptide of 50. A method of facilitating wound healing, comprising contacting a wound with a composition comprising the multi-stranded collagen-mimetic peptide of 51. The method of CROSS-REFERENCE TO RELATED APPLICATIONS
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
BACKGROUND
SUMMARY OF THE INVENTION
DESCRIPTION OF THE DRAWINGS
DETAILED DESCRIPTION
EXAMPLES
Example 1: Optimal Interstrand Bridges for Collagen-Like Biomaterials
Breakdown of Estraininto Force-Field Energy Components: CH2groups Estraincomponents (kcal/mol) Linker on linker, Van der type nXaa+ nYaa Total Bonds Angles Torsions Waals h-c 3 3.8 0.2 0.7 2.3 0.6 t-t 6 7.9 0.2 1.6 2.6 3.5 t-c 4 8.0 0.4 1.2 2.5 3.9 t-h 5 8.7 0.3 1.2 5.6 1.7 h-h 4 9.2 0.2 1.2 5.8 2.0 c-t 4 10.7 0.3 1.6 6.7 2.3 h-t 5 11.0 0.5 1.9 5.0 3.6 c-h 3 11.9 0.6 4.1 5.3 1.9 c-c 2 15.9 1.2 9.1 4.5 1.2 Side-chainaand DisulfidebTorsion Angles Along the Linker as Obtained from Computational Models Reported in Degrees: c-c h-c c-h h-h c-t h-t t-t t-h t-c Xaa Cys Hcy Cys Hcy Cys Hcy Tnv Tnv Tnv Cα | 42.5 49.8 42.2 65.6 53.8 43.1 81.9 49.2 68.1 Cβ | 81.1 73.8 112.5 102.8 113.2 160.1 159.4 152.4 −175.4 Cγ | −160.9 −168.3 −76.2 −146.9 −83.2 −165.0 Cδ | −69.7 −90.1 −60.5 S | −146.5 129.6 −114.4 81.5 −153.3 −90.9 126.6 94.7 106.3 S | 60.7 92.9 −87.5 Cδ | −49.2 −123.7 −104.3 −113.9 −62.0 −122.9 Cγ | 69.3 −79.2 104.4 129.7 135.7 149.1 169.1 149.2 −132.5 Cβ | −127.6 −71.4 −154.0 −158.9 −167.0 −170.1 −176.4 −168.2 −44.2 Cα | Yaa Cys Cys Hcy Hcy Tnv Tnv Tnv Hcy Cys aSide-chain torsion angles across C—C and C—S bonds that are closer to the eclipsed rather than the staggered conformation are shown in bold typeface. bTorsion angles across the disulfide bond are underlined for each linker, and those angles closer to energy maxima (0° and 180°) rather than minima (±90°) are shown in bold typeface. Values of Tm(° C.) for Hetero- and Homotrimers as Determined by Thermal Denaturation Experiments Monitored by Circular Dichroism Spectroscopy Strands that constitute Linker x − x − y · s2 s1x · s2 · s3y s1x + s2 + s3y type y · s2 s1x, s2, s3y (calculated)a mixture c-c 28 25, 37, 29 30 30 h-c 35 22, 37, 29 29 30 c-h 28 25, 37, 33 31 31 h-h 27 22, 37, 33 31 32 aThe estimate of the Tmfor “reduced” x − y · s2 was calculated as the average of the homotrimer Tmvalues for the related s1x, s2 and s3y strands. Example 2: Comparisons Among Interstrand Disulfide and Thioether Bridges
Estrainand its components for disulfide- and thioether-linkages (ranked by linker size, then Estrain) Estraincomponents (kcal/mol) # of bonds Linker Xaa × Yaa Total Bonds Torsion VDW btw. Cβ atoms Cβ-to- Cβ Cys × Cys 15.8 10.3 4.5 1.2 3 CSSC Hal × Cys 21.9 15.2 3.6 3.1 3 CCSC Cys × Hal 28.6 19.3 5.7 3.7 3 CSCC Hcy × Cys 3.8 0.9 2.3 0.6 4 CCSSC Hcy × Hal 6.5 1.1 3.6 1.9 4 eq. Hal × Hcy CCSCC Hal × Hcy 6.5 1.1 3.6 1.9 4 eq. Hcy × Hal CCSCC Nva × Cys 8.3 2.4 3.6 2.4 4 CCCSC Cys × Nva 9.0 1.8 4.7 2.7 4 CSCCC Cys × Hcy 11.8 4.7 5.3 1.9 4 CSSCC Tnv × Hal 7.1 2.4 2.3 2.4 5 eq. Nva × Hcy CCCSCC Nva × Hcy 7.1 2.4 2.3 2.4 5 eq. Tnv × Hal CCCSCC Tnv × Cys 8.0 1.6 2.5 3.9 5 CCCSSC Hcy × Hcy 9.2 1.3 5.8 2.0 5 CCSSCC Nle × Cys 10.0 3.9 4.4 1.7 5 CCCCSC Cys × Nle 10.6 1.7 5.6 3.3 5 CSCCCC Cys × Tnv 10.7 1.8 6.7 2.3 5 CSSCCC Hcy × Nva 11.2 1.2 6.1 3.9 5 eq. Nva × Tnv CCSCCC Hal × Tnv 11.2 1.2 6.1 3.9 5 eq. Tnv × Nva CCSCCC Hcy × Nle 6.1 0.9 3.6 1.6 6 CCSCCCC Tnv × Hcy 8.7 1.4 5.6 1.7 6 CCCSSCC Nle × Hcy 9.6 2.5 3.8 3.4 6 CCCCSCC Hcy × tnv 11.0 2.4 5.0 3.6 6 CCSSCCC Tnv × Nva 11.2 3.2 5.6 2.4 6 eq. Nva × Tnv CCCSCCC Nva × Tnv 11.2 3.2 5.6 2.4 6 eq. Tnv × Nva CCCSCCC Tnv × Nle 6.9 0.3 3.8 2.9 7 CCCSCCCC Tnv × Tnv 7.9 1.8 2.6 3.5 7 CCCSSCCC Nle × Tnv 8.8 1.3 4.1 3.4 7 CCCCSCCC Estrainand its components for disulfide- and thioether-linkages (ranked by Estrain) Estraincomponents (kcal/mol) # of bonds Linker Xaa × Yaa Total Bonds Torsion VDW btw. Cβ atoms Cβ-to- Cβ Hcy × Cys 3.8 0.9 2.3 0.6 4 CCSSC Hcy × Nle 6.1 0.9 3.6 1.6 6 CCSCCC Hcy × Hal 6.5 1.1 3.6 1.9 4 eq. Hal × Hcy CCSCC Hal × Hcy 6.5 1.1 3.6 1.9 4 eq. Hcy × Hal CCSCC Tnv × Nle 6.9 0.3 3.8 2.9 7 CCCSCCCC Tnv × Hal 7.1 2.4 2.3 2.4 5 eq. Nva × Hcy CCCSCC Nva × Hcy 7.1 2.4 2.3 2.4 5 eq. Tnv × Hal CCCSCC Tnv × Tnv 7.9 1.8 2.6 3.5 7 CCCSSCCC Tnv × Cys 8.0 1.6 2.5 3.9 5 CCCSSC Nva × Cys 8.3 2.4 3.6 2.4 4 CCCSC Tnv × Hcy 8.7 1.4 5.6 1.7 6 CCCSSCC Nle × Tnv 8.8 1.3 4.1 3.4 7 CCCCSCCC Cys × Nva 9.0 1.8 4.7 2.7 4 CSCCC Hcy × Hcy 9.2 1.3 5.8 2.0 5 CCSSCC Nle × Hcy 9.6 2.5 3.8 3.4 6 CCCCSCC Nle × Cys 10.0 3.9 4.4 1.7 5 CCCCSC Cys × Nle 10.6 1.7 5.6 3.3 5 CSCCCC Cys × Tnv 10.7 1.8 6.7 2.3 5 CSSCCC Hcy × Tnv 11.0 2.4 5.0 3.6 6 CCSSCCC Tnv × Nva 11.2 3.2 5.6 2.4 6 eq. Nva × Tnv CCCSCCC Nva × Tnv 11.2 3.2 5.6 2.4 6 eq. Tnv × Nva CCCSCCC Hcy × Nva 11.2 1.2 6.1 3.9 5 eq. Hal × Tnv CCSCCC Hal × Tnv 11.2 1.2 6.1 3.9 5 eq. Hcy × Nva CCSCCC Cys × Hcy 11.8 4.7 5.3 1.9 4 CSSCC Cys × Cys 15.8 10.3 4.5 1.2 3 CSSC Hal × Cys 21.9 15.2 3.6 3.1 3 CCSC Cys × Hal 28.6 19.3 5.7 3.7 3 CSCC Example 3: Synthetic Collagen-Like Fibers Through Self-Assembly of Chemically-Linked Triple Helices
(Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q-Hcy- Yaa-Gly-(Xaa-Yaa-Gly)r, (Xaa-Yaa-Gly)j-Xaa-Cys-Gly-(Xaa-Yaa-Gly)k
where (n+m+1)=(p+q+r+2)=(j+k+1). The top line is SEQ ID NO:17, the middle line is SEQ ID NO:21, and the bottom line is SEQ ID NO:23.The two Hcy-Cys disulfide linkages are highlighted.
(Xaa-Yaa-Gly)n-Cys-Yaa-Gly-(Xaa-Yaa-Gly)m (Xaa-Yaa-Gly)p-Xaa-Cys-Gly-(Xaa-Yaa-Gly)q-Hcy- Yaa-Gly-(Xaa-Yaa-Gly)r, (Xaa-Yaa-Gly)j-Xaa-Cys-Gly-(Xaa-Yaa-Gly)k.
The top line is SEQ ID NO:24, the middle line is SEQ ID NO:21, the bottom line is SEQ ID NO:23.This structure varies from the previous example in that the Hcy-Cys disulfide bridge between the top and middle strands has been replaced with a Cys-Cys disulfide bridge.
(Xaa-Yaa-Gly)n-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)m (Xaa-Yaa-Gly)p-Hcy-Yaa-Gly-(Xaa-Yaa-Gly)q-Xaa- Cys-Gly-(Xaa-Yaa-Gly)r, (Xaa-Yaa-Gly)j-Xaa-Cys-Gly-(Xaa-Yaa-Gly)k.
The top line is SEQ ID NO:17, the middle line is SEQ ID NO:23, and the bottom line is SEQ ID NO:23. Assembly would proceed, through sticky ends, as described above.
Example 4: Synthetic Collagen-Like Fibers Through the Self-Assembly of Chemically-Linked Strand Pairs















